Rethinking high-risk neuroblastoma treatment

被引：2
作者：
Cohn, Susan L. [1 ]
Pearson, Andrew D. J. [2 ]
机构：
[1] Univ Chicago, Dept Pediat, Sect Pediat Hematol & Oncol, Chicago, IL 60637 USA
[2] Royal Marsden Hosp, Inst Canc Res, Div Clin Studies, Sutton, Surrey, England
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 08期
关键词：
TRANSPLANTATION; CHEMOTHERAPY;
D O I：
10.1002/pbc.29730
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 17 条
  • [1] To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma
    Bird, Nicholas
    Scobie, Nicole
    Palmer, Antonia
    Ludwinski, Donna
    [J]. PEDIATRIC BLOOD & CANCER, 2022, 69 (08)
  • [2] Desai AV., CANCER
  • [3] Diller L, 2021, ADV NEUROBLASTOMA RE
  • [4] Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A
    Furman, Wayne L.
    McCarville, Beth
    Shulkin, Barry L.
    Davidoff, Andrew
    Krasin, Matthew
    Hsu, Chia-Wei
    Pan, Haitao
    Wu, Jianrong
    Brennan, Rachel
    Bishop, Michael W.
    Helmig, Sara
    Stewart, Elizabeth
    Navid, Fariba
    Triplett, Brandon
    Santana, Victor
    Santiago, Teresa
    Hank, Jacquelyn A.
    Gillies, Stephen D.
    Yu, Alice
    Sondel, Paul M.
    Leung, Wing H.
    Pappo, Alberto
    Federico, Sara M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04) : 335 - +
  • [5] Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
    Garaventa, Alberto
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Elliott, Martin
    Ash, Shifra
    Chan, Godfrey C. F.
    Laureys, Genevieve
    Beck-Popovic, Maja
    Vettenranta, Kim
    Balwierz, Walentyna
    Schroeder, Henrik
    Owens, Cormac
    Cesen, Maja
    Papadakis, Vassilios
    Trahair, Toby
    Schleiermacher, Gudrun
    Ambros, Peter
    Sorrentino, Stefania
    Pearson, Andrew D. J.
    Ladenstein, Ruth Lydia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (23) : 2552 - +
  • [6] Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue
    Haghiri, Sandrine
    Fayech, Chiraz
    Mansouri, Imene
    Dufour, Christelle
    Pasqualini, Claudia
    Bolle, Stephanie
    Rivollet, Sophie
    Dumas, Agnes
    Boumaraf, Amel
    Belhout, Amel
    Journy, Neige
    Souchard, Vincent
    Vu-Bezin, Giao
    Veres, Cristina
    Haddy, Nadia
    De Vathaire, Florent
    Valteau-Couanet, Dominique
    Fresneau, Brice
    [J]. BONE MARROW TRANSPLANTATION, 2021, 56 (08) : 1984 - 1997
  • [7] High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma
    Jodele, Sonata
    Dandoy, Christopher E.
    Myers, Kasiani
    Wallace, Gregory
    Lane, Adam
    Teusink-Cross, Ashley
    Weiss, Brian
    Davies, Stella M.
    [J]. BONE MARROW TRANSPLANTATION, 2018, 53 (10) : 1311 - 1318
  • [8] Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
    Kreissman, Susan G.
    Seeger, Robert C.
    Matthay, Katherine K.
    London, Wendy B.
    Sposto, Richard
    Grupp, Stephan A.
    Haas-Kogan, Daphne A.
    LaQuaglia, Michael P.
    Yu, Alice L.
    Diller, Lisa
    Buxton, Allen
    Park, Julie R.
    Cohn, Susan L.
    Maris, John M.
    Reynolds, C. Patrick
    Villablanca, Judith G.
    [J]. LANCET ONCOLOGY, 2013, 14 (10) : 999 - 1008
  • [9] Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
    Ladenstein, Ruth
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Yaniv, Isaac
    Laureys, Genevieve
    Brock, Penelope
    Michon, Jean Marie
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Schreier, Guenter
    Loibner, Hans
    Ambros, Peter
    Holmes, Keith
    Castellani, Maria Rita
    Gaze, Mark N.
    Garaventa, Alberto
    Pearson, Andrew D. J.
    Lode, Holger N.
    [J]. LANCET ONCOLOGY, 2018, 19 (12) : 1617 - 1629
  • [10] Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
    Ladenstein, Ruth
    Poetschger, Ulrike
    Pearson, Andrew D. J.
    Brock, Penelope
    Luksch, Roberto
    Castel, Victoria
    Yaniv, Isaac
    Papadakis, Vassilios
    Laureys, Genevieve
    Malis, Josef
    Balwierz, Walentyna
    Ruud, Ellen
    Kogner, Per
    Schroeder, Henrik
    de Lacerda, Ana Forjaz
    Beck-Popovic, Maja
    Bician, Pavel
    Garami, Miklos
    Trahair, Toby
    Canete, Adela
    Ambros, Peter F.
    Holmes, Keith
    Gaze, Mark
    Schreier, Guenter
    Garaventa, Alberto
    Vassal, Gilles
    Michon, Jean
    Valteau-Couanet, Dominique
    [J]. LANCET ONCOLOGY, 2017, 18 (04) : 500 - 514
12